Leerink Partnrs Forecasts Stronger Earnings for AnaptysBio

Key Points

• Leerink Partners has raised its Q3 2025 earnings estimate for AnaptysBio to ($0.84) per share, improving from the previous estimate of ($1.08).
• Analysts' ratings for AnaptysBio show a positive trend, with a consensus rating of "Moderate Buy" and a target price of $47.75.
• AnaptysBio reported a better-than-expected quarterly earnings result with an EPS of ($1.34), exceeding consensus estimates by $0.16.

AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Research analysts at Leerink Partnrs increased their Q3 2025 EPS estimates for shares of AnaptysBio in a research report issued to clients and investors on Wednesday, August 6th. Leerink Partnrs analyst D. Risinger now forecasts that the biotechnology company will post earnings per share of ($0.84) for the quarter, up from their prior forecast of ($1.08). The consensus estimate for AnaptysBio's current full-year earnings is ($6.08) per share. Leerink Partnrs also issued estimates for AnaptysBio's Q4 2025 earnings at ($0.67) EPS, FY2025 earnings at ($3.97) EPS, FY2026 earnings at ($1.18) EPS, FY2027 earnings at ($2.66) EPS, FY2028 earnings at ($2.14) EPS and FY2029 earnings at ($0.92) EPS.

ANAB has been the subject of several other reports. HC Wainwright upgraded shares of AnaptysBio from a "neutral" rating to a "buy" rating and boosted their target price for the company from $22.00 to $38.00 in a research note on Wednesday, June 4th. Wedbush boosted their target price on shares of AnaptysBio from $40.00 to $45.00 and gave the company an "outperform" rating in a research note on Thursday, August 7th. JPMorgan Chase & Co. boosted their target price on shares of AnaptysBio from $42.00 to $80.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Guggenheim reiterated a "buy" rating and issued a $90.00 target price (up from $54.00) on shares of AnaptysBio in a research note on Wednesday, May 28th. Finally, UBS Group reissued a "neutral" rating and issued a $20.00 price target (up previously from $18.00) on shares of AnaptysBio in a report on Tuesday. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $46.13.

AnaptysBio Stock Performance

Shares of ANAB traded down $0.63 during trading hours on Monday, hitting $20.10. The stock had a trading volume of 137,312 shares, compared to its average volume of 771,762. The firm has a 50-day moving average price of $24.08 and a 200 day moving average price of $20.52. AnaptysBio has a fifty-two week low of $12.21 and a fifty-two week high of $40.70. The firm has a market capitalization of $562.66 million, a price-to-earnings ratio of -4.48 and a beta of -0.20.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.50) by $0.16. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%. The business had revenue of $22.26 million during the quarter, compared to analysts' expectations of $11.55 million.

Institutional Trading of AnaptysBio

Several hedge funds have recently added to or reduced their stakes in the company. First Light Asset Management LLC grew its position in shares of AnaptysBio by 433.3% during the first quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company's stock worth $86,139,000 after acquiring an additional 3,764,720 shares during the last quarter. Vanguard Group Inc. grew its position in shares of AnaptysBio by 8.4% during the fourth quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock worth $24,411,000 after acquiring an additional 143,584 shares during the last quarter. Fairmount Funds Management LLC purchased a new position in shares of AnaptysBio during the fourth quarter worth approximately $24,050,000. Boxer Capital Management LLC purchased a new position in AnaptysBio in the 4th quarter valued at $17,212,000. Finally, Palo Alto Investors LP grew its position in AnaptysBio by 20.9% in the 1st quarter. Palo Alto Investors LP now owns 1,020,713 shares of the biotechnology company's stock valued at $18,975,000 after buying an additional 176,742 shares during the last quarter.

Insiders Place Their Bets

In related news, Director Hollings Renton sold 20,925 shares of the firm's stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $23.57, for a total value of $493,202.25. Following the sale, the director owned 4,965 shares of the company's stock, valued at $117,025.05. This trade represents a 80.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 33.50% of the stock is currently owned by company insiders.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.